Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.

A randomized, double-blind trial of lisinopril and losartan for the treatment of cardiomyopathy in duchenne muscular dystrophy.

Allen HD, Flanigan KM, Thrush PT, Dvorchik I, Yin H, Canter C, Connolly AM, Parrish M, McDonald CM, Braunlin E, Colan SD, Day J, Darras B, Mendell JR.

PLoS Curr. 2013 Dec 12;5. pii: ecurrents.md.2cc69a1dae4be7dfe2bcb420024ea865. doi: 10.1371/currents.md.2cc69a1dae4be7dfe2bcb420024ea865. Erratum in: PLoS Curr. 2015;7. pii: ecurrents.md.995441cf82fd58a29c6e4fdd5cd36b89. doi: 10.1371/currents.md.995441cf82fd58a29c6e4fdd5cd36b89.

2.

Prednisolone attenuates improvement of cardiac and skeletal contractile function and histopathology by lisinopril and spironolactone in the mdx mouse model of Duchenne muscular dystrophy.

Janssen PM, Murray JD, Schill KE, Rastogi N, Schultz EJ, Tran T, Raman SV, Rafael-Fortney JA.

PLoS One. 2014 Feb 13;9(2):e88360. doi: 10.1371/journal.pone.0088360. eCollection 2014 Feb 13.

3.

Eplerenone for early cardiomyopathy in Duchenne muscular dystrophy: a randomised, double-blind, placebo-controlled trial.

Raman SV, Hor KN, Mazur W, Halnon NJ, Kissel JT, He X, Tran T, Smart S, McCarthy B, Taylor MD, Jefferies JL, Rafael-Fortney JA, Lowe J, Roble SL, Cripe LH.

Lancet Neurol. 2015 Feb;14(2):153-61. doi: 10.1016/S1474-4422(14)70318-7. Epub 2014 Dec 30. Erratum in: Lancet Neurol. 2015 Feb;14(2):135.

4.

Effects of angiotensin-converting enzyme inhibitors and/or beta blockers on the cardiomyopathy in Duchenne muscular dystrophy.

Viollet L, Thrush PT, Flanigan KM, Mendell JR, Allen HD.

Am J Cardiol. 2012 Jul 1;110(1):98-102. doi: 10.1016/j.amjcard.2012.02.064. Epub 2012 Mar 29.

PMID:
22463839
5.

Oral corticosteroids and onset of cardiomyopathy in Duchenne muscular dystrophy.

Barber BJ, Andrews JG, Lu Z, West NA, Meaney FJ, Price ET, Gray A, Sheehan DW, Pandya S, Yang M, Cunniff C.

J Pediatr. 2013 Oct;163(4):1080-4.e1. doi: 10.1016/j.jpeds.2013.05.060. Epub 2013 Jul 15.

PMID:
23866715
6.

Eplerenone for early cardiomyopathy in Duchenne muscular dystrophy: results of a two-year open-label extension trial.

Raman SV, Hor KN, Mazur W, He X, Kissel JT, Smart S, McCarthy B, Roble SL, Cripe LH.

Orphanet J Rare Dis. 2017 Feb 20;12(1):39. doi: 10.1186/s13023-017-0590-8.

7.

Corticosteroids for the treatment of Duchenne muscular dystrophy.

Matthews E, Brassington R, Kuntzer T, Jichi F, Manzur AY.

Cochrane Database Syst Rev. 2016 May 5;(5):CD003725. doi: 10.1002/14651858.CD003725.pub4. Review.

PMID:
27149418
8.
9.

Precordial R wave height does not correlate with echocardiographic findings in boys with Duchenne muscular dystrophy.

Thrush PT, Edward N, Flanigan KM, Mendell JR, Allen HD.

Congenit Heart Dis. 2013 Nov-Dec;8(6):561-7. doi: 10.1111/chd.12049. Epub 2013 Mar 20.

PMID:
23510265
10.

Early treatment with lisinopril and spironolactone preserves cardiac and skeletal muscle in Duchenne muscular dystrophy mice.

Rafael-Fortney JA, Chimanji NS, Schill KE, Martin CD, Murray JD, Ganguly R, Stangland JE, Tran T, Xu Y, Canan BD, Mays TA, Delfín DA, Janssen PM, Raman SV.

Circulation. 2011 Aug 2;124(5):582-8. doi: 10.1161/CIRCULATIONAHA.111.031716. Epub 2011 Jul 18.

11.

Participation in daily life activities and its relationship to strength and functional measures in boys with Duchenne muscular dystrophy.

Bendixen RM, Lott DJ, Senesac C, Mathur S, Vandenborne K.

Disabil Rehabil. 2014;36(22):1918-23. doi: 10.3109/09638288.2014.883444. Epub 2014 Feb 6.

12.

Pharmacological therapy for the prevention and management of cardiomyopathy in Duchenne muscular dystrophy: A systematic review.

El-Aloul B, Altamirano-Diaz L, Zapata-Aldana E, Rodrigues R, Malvankar-Mehta MS, Nguyen CT, Campbell C.

Neuromuscul Disord. 2017 Jan;27(1):4-14. doi: 10.1016/j.nmd.2016.09.019. Epub 2016 Oct 11.

PMID:
27815032
13.

Effects of steroids and angiotensin converting enzyme inhibition on circumferential strain in boys with Duchenne muscular dystrophy: a cross-sectional and longitudinal study utilizing cardiovascular magnetic resonance.

Hor KN, Mazur W, Taylor MD, Al-Khalidi HR, Cripe LH, Jefferies JL, Raman SV, Chung ES, Kinnett KJ, Williams K, Gottliebson WM, Benson DW.

J Cardiovasc Magn Reson. 2011 Oct 19;13:60. doi: 10.1186/1532-429X-13-60.

14.

Effects of modulators of the renin-angiotensin-aldosterone system on cough. Losartan Cough Study Group.

Lacourcière Y, Brunner H, Irwin R, Karlberg BE, Ramsay LE, Snavely DB, Dobbins TW, Faison EP, Nelson EB.

J Hypertens. 1994 Dec;12(12):1387-93.

PMID:
7706699
15.

Correlation of heart rate and cardiac dysfunction in Duchenne muscular dystrophy.

Thomas TO, Morgan TM, Burnette WB, Markham LW.

Pediatr Cardiol. 2012 Oct;33(7):1175-9. doi: 10.1007/s00246-012-0281-0. Epub 2012 Mar 21.

PMID:
22434508
16.

Chronic losartan administration reduces mortality and preserves cardiac but not skeletal muscle function in dystrophic mice.

Bish LT, Yarchoan M, Sleeper MM, Gazzara JA, Morine KJ, Acosta P, Barton ER, Sweeney HL.

PLoS One. 2011;6(6):e20856. doi: 10.1371/journal.pone.0020856. Epub 2011 Jun 22.

17.

Myostatin inhibitor ACE-031 treatment of ambulatory boys with Duchenne muscular dystrophy: Results of a randomized, placebo-controlled clinical trial.

Campbell C, McMillan HJ, Mah JK, Tarnopolsky M, Selby K, McClure T, Wilson DM, Sherman ML, Escolar D, Attie KM.

Muscle Nerve. 2016 Jul 27. doi: 10.1002/mus.25268. [Epub ahead of print]

PMID:
27462804
18.
19.

Myocardial Fibrosis Progression in Duchenne and Becker Muscular Dystrophy: A Randomized Clinical Trial.

Silva MC, Magalhães TA, Meira ZM, Rassi CH, Andrade AC, Gutierrez PS, Azevedo CF, Gurgel-Giannetti J, Vainzof M, Zatz M, Kalil-Filho R, Rochitte CE.

JAMA Cardiol. 2017 Feb 1;2(2):190-199. doi: 10.1001/jamacardio.2016.4801.

PMID:
27926769
20.

Circumferential strain analysis identifies strata of cardiomyopathy in Duchenne muscular dystrophy: a cardiac magnetic resonance tagging study.

Hor KN, Wansapura J, Markham LW, Mazur W, Cripe LH, Fleck R, Benson DW, Gottliebson WM.

J Am Coll Cardiol. 2009 Apr 7;53(14):1204-10. doi: 10.1016/j.jacc.2008.12.032.

Supplemental Content

Support Center